Crohn Disease

Phase II Trial results for treatment of Crohn Disease with Cimzia are positive

Published in Clinical Trials Week, November 14th, 2005

A single 400 mg injection of Cimzia (certolizumab pegol, CDP 870) every 4 weeks was effective in maintaining control of the signs and symptoms of Crohn disease following induction therapy, according to pivotal phase III research presented recently at the annual meeting of the American College of Gastroenterology.

The study, entitled PRECiSE 2, found that a significantly higher proportion of patients who responded to an induction regimen of 400 mg Cimzia(tm) at weeks zero, two and six, were able to maintain clinical response and achieve remission by week 26 when given a single injection every 4 weeks, compared to those treated with placebo. A regulatory submission for...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Clinical Trials Week

Source: Clinical Trials Week (2005-11-14)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry